Skip to main content

The artificial pancreas in children aged 1 to 7 years with type 1 diabetes

Objective

TYPE 1 DIABETES is one of the most COMMON CHRONIC diseases in children with a RAPID increase in number of cases particularly in young children. Type 1 diabetes is associated with LIFE-LONG dependency on insulin administration. POOR glucose control leads to diabetes COMPLICATIONS, e.g. eye, heart, kidney disease, including BRAIN changes in young children. Episodes of VERY LOW glucose levels may be life threatening and are a major complication.

The ARTIFICIAL PANCREAS addresses the problem of LOW and HIGH glucose levels by delivering insulin BELOW and ABOVE pre-set amounts according to real-time sensor GLUCOSE levels, combining glucose SENSOR, insulin PUMP, and CONTROL ALGORITHM. The Artificial pancreas promises to TRANSFORM management of type 1 diabetes but EVIDENCE supporting its use during FREE LIVING in YOUNG CHILDREN is MISSING.

The project evaluates the biomedical, psychosocial, and cost effectiveness of NOVEL INDIVIDUALISED artificial pancreas in young children aged 1 to 7 years with type 1 diabetes. Following a PILOT (n=24), in the MAIN study (n=94) half of the participants (n=47) will be treated over 12 MONTHS by the ARTIFICIAL PANCREAS and the other half (n=47) by STATE-OF-THE-ART PREDICTIVE LOW GLUCOSE MANAGEMENT insulin pump therapy. Each treatment will last ONE YEAR. QUALITY OF LIFE will be assessed and semi-structured INTERVIEWS conducted to understand the impact on daily life. HEALTH TECHNOLOGY ASSESSMENT will support reimbursement.

The project will OPTIMISE artificial pancreas and SPEARHEAD SYSTEM-WIDE improvements in health care quality and health outcomes in YOUNG CHILDERN with TYPE 1 DIABETES who live with the disease LONGEST. By IMPROVING THERAPEUTIC OUTCOMES, the project will CHANGE clinical practice and INFLUENCE national and international treatment guidelines making the artificial pancreas WIDELY ACCEPTABLE as the state-of-art treatment modality in young children.

Field of science

  • /medical and health sciences/medical biotechnology/tissue engineering/artificial pancreas
  • /medical and health sciences/clinical medicine/endocrinology/diabetes

Call for proposal

H2020-SC1-2016-RTD
See other projects for this call

Funding Scheme

RIA - Research and Innovation action

Coordinator

THE CHANCELLOR MASTERS AND SCHOLARSOF THE UNIVERSITY OF CAMBRIDGE
Address
Trinity Lane The Old Schools
CB2 1TN Cambridge
United Kingdom
Activity type
Higher or Secondary Education Establishments
EU contribution
€ 1 567 828,75

Participants (10)

MEDIZINISCHE UNIVERSITAT GRAZ
Austria
EU contribution
€ 441 191,25
Address
Auenbruggerplatz 2
8036 Graz
Activity type
Higher or Secondary Education Establishments
CENTRE HOSPITALIER DE LUXEMBOURG
Luxembourg
EU contribution
€ 399 025
Address
Rue Nicolas Ernest Barble 4
1210 Luxembourg
Activity type
Public bodies (excluding Research Organisations and Secondary or Higher Education Establishments)
UNIVERSITAET LEIPZIG
Germany
EU contribution
€ 399 025
Address
Ritterstrasse 26
04109 Leipzig
Activity type
Higher or Secondary Education Establishments
MEDIZINISCHE UNIVERSITAT INNSBRUCK
Austria
EU contribution
€ 399 025
Address
Christoph Probst Platz 1
6020 Innsbruck
Activity type
Higher or Secondary Education Establishments
THE LEEDS TEACHING HOSPITALS NATIONAL HEALTH SERVICE TRUST
United Kingdom
EU contribution
€ 399 025
Address
St James's University Hospital, Beckett Street
LS9 7TF Leeds
Activity type
Public bodies (excluding Research Organisations and Secondary or Higher Education Establishments)
MEDIZINISCHE UNIVERSITAET WIEN
Austria
EU contribution
€ 430 275
Address
Spitalgasse 23
1090 Wien
Activity type
Higher or Secondary Education Establishments
THE UNIVERSITY OF EDINBURGH
United Kingdom
EU contribution
€ 325 458,75
Address
Old College, South Bridge
EH8 9YL Edinburgh
Activity type
Higher or Secondary Education Establishments
VYOO AGENCY
France
EU contribution
€ 93 780
Address
10, Rue Yvonne
69100 Villeurbanne
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
JAEB CENTER FOR HEALTH RESEARCH FOUNDATION INC
United States
EU contribution
€ 0
Address
15310 Amberly Drive Suite 350
33647 Tampa
Activity type
Research Organisations
DIASEND AB
Sweden
EU contribution
€ 182 843,75
Address
Datavagen 14A
43632 Askim
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)